title: Primary cutaneous aspergillosis (PCA)--a case report.
abstract: Primary cutaneous aspergillosis is a rare diagnosis. Predisposing factors are immunodeficiency and macerated skin. The mortality of infections with Aspergillus species is high, especially in neonatal intensive care units (NICUs). We present a premature (24 wk of gestation) infant with primary cutaneous aspergillosis appearing on the sixth day of life. Predisposing factors in this patient were prematurity, extremely vulnerable skin, treatment with antibiotics and renovation in the radiology department nearby. The patient was treated with amphotericin B intravenously for a total of 40 d. He did not have, nor develop, disseminated aspergillosis, and suffered no side effects from the treatment. The only remaining trace of his infection was scarring in the affected area.
  
  
  CONCLUSIONS
  After having treated this patient successfully and having gone through the available literature, we conclude that treating primary cutaneous aspergillosis with intravenous amphotericin B prevents disseminated aspergillosis and is the treatment of choice.
authors.affiliation: Department of Paediatrics, Rikshospitalet, Oslo, Norway. jannicke.hanne.andresen@rikshospitalet.no
authors.forename: Jannicke
authors.initials: J
authors.lastname: Andresen
authors.forename: Egil André
authors.initials: EA
authors.lastname: Nygaard
authors.forename: Ketil
authors.initials: K
authors.lastname: Størdal
mesh_terms: D000666:Amphotericin B / Q000008:administration & dosage; D001228:Aspergillosis / Q000188:drug therapy*; D003881:Dermatomycoses / Q000188:drug therapy*; D004200:Diseases in Twins / Q000188:drug therapy*; D006801:Humans; D007231:Infant, Newborn; D007235:Infant, Premature, Diseases / Q000188:drug therapy*; D008297:Male
chemical_list: D000666:Amphotericin B